188体育

  • 188体育_188体育盘口

    188体育_188体育盘口服务专线

    188体育_188体育盘口
    188体育 > 国外科技 >

    佳能s95报价APresentforNIH-PresidentSignsLawCatingNewTranslationalCer

    文章来源:Erron   时间:2020-01-06

      佳能s95报价A Present for NIH- President Signs Law Creating New Translational CenterA Present for NIH: President Signs Law Creating New Translational Center A year after advisers made the proposal and following months of controversy, the National Institutes of Health (NIH) has secured a new translational research center. The final step came just before Christmas when President Barack Obama signed a $1 trillion 2012 spending bill on 23 December that includes funding for NIH. The bill also launches the National Center for Advancing Translational Sciences (NCATS)—backed by NIH Director Francis Collins—which will aim to push basic discoveries more quickly to the clinic by "reengineering" the drug development process. The creation of NCATS roiled the biomedical research community partly because the reorganization dismantles the National Center for Research Resources, which had many staunch supporters. Some industry leaders were also concerned that NIH funding would tilt away from basic science toward drug development, which they say academic scientists are not suited to do. Many scientific leaders in industry still feel that way, says Roy Vagelos, a former CEO of Merck. "The generation of new knowledge is crucial" to drug discovery, Vagelos says. "If academia stops doing it, nobody will do it." NIHs press release acknowledges this worry, vowing that the ratio of basic and applied research at NIH "will not be disturbed" by the creation of NCATS. NCATS supporters, meanwhile, are thrilled that NCATS is finally real. Amy Comstock Rick, CEO of the Parkinsons Action Network, says her group isnt too concerned about language in the spending bill that states that NCATS cannot fund clinical trials that go beyond a certain stage. "Im quite sure they can work within it," she says. The $575 million NCATS will start out as a collection of existing programs transferred from NCRR and other institutes. The one new program in NCATS—the Cures Acceleration Network—received only $10 million in the spending bill, far less than advocates such as Rick had hoped for. But that should be enough to get started, says Rick. Shes also excited by plans for NCATs advisory council, which will include representatives from industry and patient groups. "Its a new and different kind of council," she says. A memo from Collins to the staff announcing the creation of NCATS accidentally went out 6 days early. That memo also announced NCATs temporary leaders: the acting director will be Thomas Insel, director of the National Institute of Mental Health; the acting deputy director will be Kathy Hudson, NIH deputy director for science, outreach, and policy. NIH began searching for NCATSs first director this fall.